Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA)

J Clin Endocrinol Metab. 2000 Jan;85(1):76-80. doi: 10.1210/jcem.85.1.6228.


To metabolically characterize patients with slowly progressing autoimmune diabetes (LADA) of short duration we measured insulin, C peptide, and glucagon responses to glucose and arginine at three blood glucose levels (fasting and 14 and 28 mmol/L) in 11 patients with LADA, 11 patients with type 2 diabetes, and 14 healthy control subjects matched for age and body mass index. The acute insulin response to arginine was impaired in LADA vs. type 2 diabetes at all glucose levels, with the greatest impairment in the maximally stimulated insulin concentrations (P<0.04). In contrast, beta-cell sensitivity to glucose was unaltered in LADA and type 2 diabetes. The glucagon concentrations were elevated in both LADA and type 2 diabetic patients compared with healthy control subjects (P<0.02), but did not differ between the diabetic groups. In conclusion, patients with LADA share insulin resistance with type 2 diabetic patients, but display a more severe defect in maximally stimulated beta-cell capacity than patients with type 2 diabetes.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginine
  • Blood Glucose / metabolism
  • C-Peptide / blood
  • Diabetes Mellitus, Type 1 / metabolism*
  • Diabetes Mellitus, Type 2 / metabolism
  • Female
  • Glucagon / blood*
  • Glucose
  • Humans
  • Insulin / blood*
  • Male


  • Blood Glucose
  • C-Peptide
  • Insulin
  • Glucagon
  • Arginine
  • Glucose